<http://linked.opendata.cz/resource/sukl/spc/sentence/SPC154378_doc-4-5-2-1>	<http://salt.semanticauthoring.org/ontologies/sdo#hasTextChunk>	<http://linked.opendata.cz/resource/sukl/spc/text-chunk/SPC154378_doc-4-5-2-1-4295-4310> .
<http://linked.opendata.cz/resource/sukl/spc/sentence/SPC154378_doc-4-5-2-1>	<http://salt.semanticauthoring.org/ontologies/sdo#hasStartPointer>	"4057"^^<http://www.w3.org/2001/XMLSchema#long> .
<http://linked.opendata.cz/resource/sukl/spc/sentence/SPC154378_doc-4-5-2-1>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://salt.semanticauthoring.org/ontologies/sdo#Sentence> .
<http://linked.opendata.cz/resource/sukl/spc/sentence/SPC154378_doc-4-5-2-1>	<http://salt.semanticauthoring.org/ontologies/sdo#hasTextChunk>	<http://linked.opendata.cz/resource/sukl/spc/text-chunk/SPC154378_doc-4-5-2-1-4057-4065> .
<http://linked.opendata.cz/resource/sukl/spc/sentence/SPC154378_doc-4-5-2-1>	<http://salt.semanticauthoring.org/ontologies/sdo#hasText>	"Ekonazol je zn\u00E1m\u00FD inhibitor CYP3A4/2C9. Vzhledem k\u00A0omezen\u00E9 syst\u00E9mov\u00E9 dostupnosti po vagin\u00E1ln\u00ED aplikaci (viz. bod 5.2. Farmakokinetick\u00E9 vlastnosti) je v\u00FDskyt klinicky relevantn\u00EDch interakc\u00ED nepravd\u011Bpodobn\u00FD, byly v\u0161ak hl\u00E1\u0161eny u peror\u00E1ln\u00EDch antikoagulanci\u00ED."@cs .
<http://linked.opendata.cz/resource/sukl/spc/sentence/SPC154378_doc-4-5-2-1>	<http://salt.semanticauthoring.org/ontologies/sdo#hasOrderNumber>	"1"^^<http://www.w3.org/2001/XMLSchema#int> .
<http://linked.opendata.cz/resource/sukl/spc/sentence/SPC154378_doc-4-5-2-1>	<http://salt.semanticauthoring.org/ontologies/sdo#hasEndPointer>	"4311"^^<http://www.w3.org/2001/XMLSchema#long> .